Next Article in Journal
Industrially Relevant Enzyme Cascades for Drug Synthesis and Their Ecological Assessment
Next Article in Special Issue
Orofacial Pain: Molecular Mechanisms, Diagnosis, and Treatment 2021
Previous Article in Journal
Synthesis of Secretory Proteins in Yarrowia lipolytica: Effect of Combined Stress Factors and Metabolic Load
Previous Article in Special Issue
TNF-α-Mediated RIPK1 Pathway Participates in the Development of Trigeminal Neuropathic Pain in Rats
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 7
10.3390/ijms23073604
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Molecular Basis and Pathophysiology of Trigeminal Neuralgia

by
QiLiang Chen
1,
Dae Ik Yi
1,
Josiah Nathan Joco Perez
1,
Monica Liu
1,
Steven D. Chang
2,
Meredith J. Barad
1,
Michael Lim
2 and
Xiang Qian
1,*
1
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2
Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(7), 3604; https://doi.org/10.3390/ijms23073604
Submission received: 16 February 2022 / Revised: 19 March 2022 / Accepted: 21 March 2022 / Published: 25 March 2022
(This article belongs to the Special Issue Orofacial Pain: Molecular Mechanisms, Diagnosis and Treatment 2021)
Versions Notes

Abstract

:
Trigeminal neuralgia (TN) is a complex orofacial pain syndrome characterized by the paroxysmal onset of pain attacks in the trigeminal distribution. The underlying mechanism for this debilitating condition is still not clearly understood. Decades of basic and clinical evidence support the demyelination hypothesis, where demyelination along the trigeminal afferent pathway is a major driver for TN pathogenesis and pathophysiology. Such pathological demyelination can be triggered by physical compression of the trigeminal ganglion or another primary demyelinating disease, such as multiple sclerosis. Further examination of TN patients and animal models has revealed significant molecular changes, channelopathies, and electrophysiological abnormalities in the affected trigeminal nerve. Interestingly, recent electrophysiological recordings and advanced functional neuroimaging data have shed new light on the global structural changes and the altered connectivity in the central pain-related circuits in TN patients. The current article aims to review the latest findings on the pathophysiology of TN and cross-examining them with the current surgical and pharmacologic management for TN patients. Understanding the underlying biology of TN could help scientists and clinicians to identify novel targets and improve treatments for this complex, debilitating disease.

1. Introduction

Trigeminal neuralgia (TN), previously known as tic douloureux, is a chronic neuropathic pain syndrome characterized by recurrent unilateral lancinating facial pain limited to the distribution of the trigeminal nerve dermatome [1]. It is a debilitating condition with severe pain and an unpredictable course that negatively impacts patients [2,3,4]. Patients with TN are often anxious about pain episodes, which discourages them from performing basic daily routines such as talking, eating, brushing teeth, and even participating in social activities. Overall, patients with TN undergo a significant amount of stress, which may lead to anxiety and depression, resulting in poor quality of life [5,6,7,8,9,10].
Traditionally, TN has been a clinical diagnosis, based on patient-reported symptoms [11]. However, advancement in clinical and basic science research has led to a deeper understanding of TN anatomy, pathophysiology, and symptomatology, which has helped to delineate the different subtypes of the disease. Most recently, the International Headache Society (IHS) and International Association for the Study of Pain (IASP) established a new classification system for TN, which includes subtypes of classical TN, secondary TN, and idiopathic TN [1]. This classification scheme aims to incorporate the current understanding of the pathophysiology of the disease with decades of clinical experiences to better aid physicians in effectively diagnosing TN subtypes and thereby guiding treatments based on the diagnosis.
The current article aims to review our current understanding of the basic mechanism of the disease and cross-examine these new data with the disease symptomatology and the current management strategies. Lastly, the outlook for future research and clinical practice will also be briefly discussed.

2. Clinical Features

2.1. Epidemiology

The recurring, episodic, and unpredictable clinical course of TN makes it difficult to determine the exact incidence of the disease. The estimated incidence of TN ranges from 4.3 to 26.8 per 100,000 person-years, with a lifetime prevalence of 0.03% to 0.3% [2,3,4,12,13]. Although the causes are not fully elucidated, the incidence of TN in women is higher than men, and the average age of onset is 53, with the most affected ages between 37 and 67 [3,12,13,14,15]. Most cases of TN are sporadic without apparent risk factors. However, there have been a few reports of familial TN [16,17], which have led to investigations of the possible genetic and molecular basis to the pathophysiology of TN.

2.2. Symptomology

TN can be debilitating because it causes a significant amount of pain in the orofacial region that is often disabling to the patient. The paroxysmal electric or stabbing pain attacks are transient and episodic, lasting less than 10 to 15 s [14,18,19]. These attacks are usually unilateral, although there are rare cases where the bilateral trigeminal nerves are involved [4,14,20]. The most affected branches of the trigeminal nerves are the maxillary (V2) and the mandibular (V3) branch, or a combination of the two, with the ophthalmic branch (V1) rarely affected [4,15,21]. A refractory phase of the pain-free period will follow after a series of pain attacks, although the length of the refractory period varies amongst patients [14]. Interestingly, recent studies revealed that 30 to 49% of patients endorsed a concomitant continuous dull, throbbing, and burning pain, with an onset of 1.5 years after the initial symptoms [15,19].
One of the major reasons why TN is debilitating is that normal daily activities can trigger severe pain. The most frequent triggering factors were touching the face, talking, chewing, or brushing teeth [5,10]. Although TN is known to be precipitated by innocuous stimuli, a study showed that a few percent of patients reported unusual trigger maneuvers, including flexing the trunk, contact with hot or cold food/water, speaking loudly, and turning of the eyes [5]. About a third of patients experienced autonomic symptoms, such as conjunctival tearing or injection on the ipsilateral side during TN attacks [14,18]. Other symptoms include edema and local flushing in the distribution of the trigeminal nerves that are affected [19]. Unsurprisingly, TN can impose significant psychosocial stress on patients and negatively impact their quality of life. Many patients suffering from TN endorse higher rates of anxiety and depression [6,9].

2.3. Clinical Classifications

TN-related symptoms have been described in historical documents as early as in the sixteenth century [22]. It was not until the late 20th century that the disease was further subclassified based on its attack characteristics into typical TN and atypical TN [23,24]. Typical TN was described as sharp, electrical, paroxysmal, and primarily located in the V2 and V3 regions of the trigeminal nerve, whereas atypical TN was dull, constant, and located in all three divisions (Table 1). However, it was challenging to guide treatment based on this classification scheme. Fortunately, the classification of TN has since evolved as our understanding of TN also broadened significantly with scientific advances within the past decades.
The rapid technological development of magnetic resonance imaging (MRI) has helped identify some of the appreciable anatomical changes in TN, which facilitated the new classification scheme [25]. High-resolution images revealed that neurovascular compression at the trigeminal nerve root entry zone correlates strongly with TN symptoms and anatomical nerve changes such as nerve atrophy, dislocation, indentation, or flattening [26,27]. Similar anatomical changes are also observed in TN associated with other primary demyelinating disorders [28,29,30,31]. To create a classification of TN that is more universally accepted among clinicians and academics, both the International Headache Society (IHS) and the International Association for the Study of Pain (IASP) incorporated these observations and published new classifications in 2018 [1,32,33]. They currently describe TN as a disorder presented with recurrent abrupt-onset unilateral brief electric shock-like pains triggered by innocuous stimuli that limit the distribution of one or more divisions of the trigeminal nerve [1]. They further classified TN into three subgroups (e.g., classical, secondary, and idiopathic TN) based on anatomical and electrophysiological findings (Table 1).
In addition to the IHS and IASP classifications, other groups also independently published classifications of TN-related facial pain. For example, Burchiel and colleagues classified facial pain syndromes into seven categories to help develop a framework to better diagnose and treat different types of TN based on the pain characteristic or the inciting event. Burchiel’s classification includes TN type I (sharp, electrical shock-like, episodic pain due to neurovascular compression of TN), TN type II (aching, throbbing, burning, constant pain >50% of the time), TN due to injury (e.g., trauma, post-surgical pain), TN secondary to multiple sclerosis, infection-related postherpetic TN, and atypical somatoform facial pain [34,35]. This unique classification scheme aims to personalize treatment recommendations based on accurate patient history, although further studies are required to verify its clinical utility.

3. Pathophysiology of Trigeminal Neuralgia

3.1. Compression of the Trigeminal Nerve Root

Classical TN is defined by focal neurovascular compression of the trigeminal nerve structure, usually occurring at the junction of the peripheral trigeminal nerve and root by vasculatures at the prepontine cistern within the Meckel’s cave [1,36]. While direct contact with arteries or veins on the trigeminal nerve root is the most common compressive mechanism, other space-occupying lesions, such as arteriovenous malformation, aneurysm, vestibular schwannoma, meningioma, and other types of cysts and tumors can also lead to trigeminal nerve compression [1,27,37,38,39,40,41]. While direct compression on the trigeminal nerve root has long been hypothesized to be the primary trigger for classical TN, the cascade of reactions that follows and the fundamental mechanism through which they lead to TN symptoms are still not well understood.
Histological examinations of the trigeminal nerve in classical TN patients have provided clues on the pathogenesis of the disease. Compression of the trigeminal nerve is associated with a significant level of myelin erosion and disintegration from inflammation, particularly at the nerve indentation area [42,43,44,45,46]. This structural abnormality is related to pathologic demyelination and remyelination of the injured nerve, a common feature in humans with peripheral nerve compression and animal models of chronic nerve compression [47,48,49,50,51]. Furthermore, Devor and colleagues reported Schmidt-Lanterman incisures in trigeminal nerve root biopsies from TN patients, consistent with a pathologic increase in metabolic demand for myelin sheath growth and maintenance found in chronic nerve compression [52,53]. Finally, there is evidence of axonal dystrophy and Schwann cell damage associated with trigeminal nerve compression [45,51,54,55,56].
Subsequently, these compression-related structural changes trigger several crucial downstream effects that play an important role in developing TN symptoms. Dysregulation of voltage-gated sodium (Nav) channels is functionally linked to TN [57]. Both preclinical animal models of classical TN and biopsies from TN patients showed a significant upregulation of Nav1.3 [58,59,60]. While Nav1.3 is an embryotic channel type normally suppressed in adults, its overexpression has been associated with several neuropathic pain conditions [61,62]. Electrophysiological recording of Nav1.3 demonstrated rapid and persistent channel activations in response to electrical stimulation [63]. This unique channel mechanic of Nav1.3 could be a major contributor to the enhanced sensitivity and ectopic impulse generation in a compressed trigeminal nerve.
In contrast, downregulation of Nav1.7 in the trigeminal nerve root is found in TN patients and preclinical TN models [58,59,60]. Nav1.7’s channel mechanic is characterized by fast inactivation and slow recovery, making it resistant to repetitive action potentials [64]. Furthermore, Nav1.7 can respond to graded potentials while in its prolonged close-gated inactivated state, which functionally translates it into a threshold channel [64]. Therefore, decreased Nav1.7 expression in the context of Nav1.3 upregulation could further increase neuronal excitability and impair normal nociceptive responses in TN. Upregulation of other Nav channels, such as Nav1.1, has recently been shown to associate with the hyperactivity of the trigeminal nerve in a chronic constricted nerve injury model in rodents [65]. However, the precise mechanism of these Nav channel dysregulations and dysfunctions contributing to symptomatic TN need to be further characterized. Additionally, hyperexcitability in trigeminal neurons secondary to the dysregulation of the resting potential mediated by the voltage-gated potassium channel has been identified in preclinical models of classical TN [66]. Lastly, Gupta and colleagues demonstrated significant apoptosis and persistent downregulation of myelin-associated glycoprotein in Schwann cells following chronic nerve compression injury [49,67]. Given Schwann cells’ ability to inhibit axonal growth via their expression of myelin-associated glycoprotein, loss of such intrinsic growth regulation could lead to the axonal sprouting seen in classical TN [45,51,54,55,68]. Indeed, this compression-induced axonal pathology provides the mechanistic basis for nerve regeneration techniques, such as type-I collagen implantation, as a potential treatment for TN [69].
The channelopathies and pathologic changes in the architectures of afferent neurons subsequently result in functional hyperexcitability of the trigeminal nerve observed in TN. Indeed, recording of trigeminal nerve roots in models of classical TN demonstrated ectopic generations of action potentials and prolonged after-discharges in demyelinated neurons [70,71,72,73]. These ectopic discharges are thought to be further amplified and spread through ephaptic cross-talking between demyelinated fibers, even between functionally distinctive neurons (e.g., A-beta afferents and nociceptive C-fibers) [74,75,76,77]. Taking these data together, Devor and colleagues proposed the “ignition hypothesis” to provide a pathophysiological explanation for the clinical characteristics of classical TN [78]. Briefly, demyelination and hyperexcitability of trigeminal neurons following neurovascular compression decrease the triggering threshold for activation of sensory afferents. During a paroxysmal attack in TN, a normally innocuous stimulus on the triggering area would lead to amplified trigeminal afferent inputs by the means of prolonged discharges and ephaptic cross-talks between the demyelinated axons. Such an attack could slowly subside if the offending stimulus is removed or the triggering threshold is raised, such as through pharmacological blockade of dysfunctional channels or functional recovery after vascular decompression surgery [78].

3.2. Primary Demyelinating Diseases

Although neurovascular compression accounts for most TN cases, primary demyelination disorders, such as multiple sclerosis, can also lead to TN symptoms. It has been well documented that patients with MS are at a higher risk of developing neuropathic pain and are estimated to be twenty times more likely to develop TN than the general population [79,80]. Pathological examinations and radiological evidence from MS patients with TN have demonstrated significant inflammatory demyelination at the trigeminal nerve root [28,29,30,81,82]. Concurrent neurovascular compression on the trigeminal nerve in MS patients could accelerate demyelination through both mechanical and inflammatory mechanisms, which lead to TN symptoms [83,84]. These observations lead to the theory of demyelinating plaque formation at the trigeminal nerve root being the main cause of TN symptoms in MS patients through a similar mechanism as in compression-related TN [29,83].
However, it has also been speculated that central demyelinating lesions can also independently lead to TN. Intrapontine demyelination along the trigeminal afferent and the trigeminal nucleus has been associated with TN symptoms in patients with MS or a brainstem infarction [31,85,86,87,88,89,90]. Although neurovascular compression is occasionally found concurrently in these patients [83,84], demyelination of the primary trigeminal afferent intrapontine trigeminal nucleus alone is sufficient to lead to TN [91]. Furthermore, at least a subset of these patients with comorbid TN and MS had lesions in second-order sensory neurons in the brainstem ipsilateral to the affected side, which are thought to cause trigeminal pain and other facial sensory disturbances [29,92].

3.3. Sensitization and Dysfunction of Central Pain-Related Circuits

Central sensitization is a process through which the nociceptive system becomes hyperexcitable or a state of hyperexcitability, and it has been implicated in various chronic pain conditions [93,94]. With the advancement of electrophysiological and advanced functional imaging techniques, researchers are now able to closely examine the sensitization of central nociceptive and affective processing in patients with classical or idiopathic TN.
Amplified nociceptive signal transmission is found in TN patients. In a series of electrophysiological recordings in TN patients with concomitant chronic facial pain, Obermann and colleagues demonstrated that pain-related evoked potentials are significantly augmented in all trigeminal divisions on both symptomatic and non-symptomatic sides [95]. This finding suggests that sensitization of the trigeminal pathway as well as the supraspinal pain-modulating circuits may be an important part of TN pathophysiology.
Functional imaging data in TN patients has also helped further delineate the involvement of pain-related supraspinal structures. Unsurprisingly, painful attacks in TN patients lead to increased activity in the trigeminal nuclei, thalamus, and somatosensory cortices—areas that are classically associated with pain-related sensory processing [96]. Moreover, multiple vital structures related to pain modulation, emotion, and memory are also activated during the attacks. These structures include the anterior cingulate cortex, insula cortex, prefrontal cortex, hippocampus, limbic system, and the brainstem pain-modulation system [96,97]. Sensitization in some of these structures has been implicated in other chronic pain conditions [93,94,98,99]. Furthermore, structural and functional neuroimaging data revealed significant alterations in functional connectivity of the frontal-limbic circuit and a gray matter reduction in pain-modulating, sensory-motor, and affective circuits in TN patients compared with healthy subjects [97,100]. Interestingly, these pathological changes are often reversed after successful treatments, suggesting changes in these circuits not only link to the characteristic pain symptoms but also the psychocognitive aspect of the disease [96,97].

4. Treatment

4.1. Medical Therapies

4.1.1. Maintenance Therapy

Anticonvulsant medications form the mainstay of medical therapies for TN. Of these, the best evidence exists for carbamazepine, which has been found to be effective in multiple randomized controlled trials [101,102,103]. Oxcarbazepine, a structural analog of carbamazepine, is also considered an effective first-line medical treatment [104]. Targeting the channelopathy seen in TN, carbamazepine and oxcarbazepine are both Nav blockers aiming to stabilize hyperexcited neuronal membranes and reduce ectopic nociceptive signaling. Despite their effectiveness, the use of both medications is often limited by their side effects, which include drowsiness, dizziness, rash, ataxia, elevated liver enzymes, hematologic dyscrasias, and hyponatremia. A recent study demonstrated that oxcarbazepine might be better tolerated than carbamazepine, although any side effects may be seen with either medication [105].
If the first-line anticonvulsants are ineffective or poorly tolerated, other anticonvulsive agents, including lamotrigine, gabapentin, and pregabalin, can also be considered as second agents or as monotherapy [104]. Lamotrigine, another Nav blocker, has demonstrated an analgesic effect in a small group of patients with refractory TN when added as a second agent [106]. The evidence for using gabapentin, a voltage-gated calcium channel blocker, in TN was summarized in a meta-analysis comparing it with carbamazepine [107]. With sixteen Chinese studies included, this meta-analysis provides low- to moderate-quality evidence that gabapentin may be as effective as carbamazepine while generally being better tolerated with fewer side effects [107]
Trigger point injections have also been explored as a maintenance strategy. For example, when used in conjunction with gabapentin, injection of ropivacaine, a local anesthetic, into facial TN pain trigger points has been shown to provide lasting pain relief for at least 28 days [108]. Multiple randomized controlled trials have demonstrated that injection of botulinum toxin A, a neurotoxin derived from the bacteria Clostridium botulinum, is an effective maintenance treatment for TN [109,110,111,112]. By injecting the toxin directly into the trigger points, it is thought to produce a lasting analgesic effect via lesioning the hyperactive fibers in the affected trigeminal branches [112,113]. Single treatments have been shown to significantly improve anxiety, depression, sleep, pain, and the number of attacks per day for up to 12 weeks [111,114]. However, due to its neurotoxic and paralytic effect, patients often report facial asymmetry with dynamic movement and facial edema after botulinum toxin injections [111].
Lastly, manual acupuncture and electroacupuncture, based on traditional Chinese medicine concepts, could be effective adjunct therapies for TN [115]. It was hypothesized that stimulation of peripheral acupuncture points leads to central nociceptive modulation and upregulation of the endogenous opioid system [115,116]. However, it is important to note that high-quality clinical evidence supporting these techniques is still lacking. A recent meta-analysis of 33 randomized controlled trials in China found mixed results for the use of acupuncture in TN [117]. Most of the trials included in the meta-analysis found that acupuncture techniques effectively reduce TN pain attack intensity and recurrence rate and may even be synergistic when combined with carbamazepine, an anticonvulsant [117]. However, the authors caution against the widespread use of acupuncture for TN due to the subpar quality of the currently available trials [117]. Indeed, the clinical application of acupuncture outside of China remains controversial. Most clinical trials are limited by their small sample size, non-blinding design, short follow-up period, and non-standardized measurement of outcomes. Furthermore, critics of acupuncture argue that trials conducted in China might have an inherent cultural bias favoring the technique and could be difficult to control [115]. Thus, establishing reliable basic science models for acupuncture and conducting large-scale multi-region trials with standardized outcome measurements and long-term follow-up could help delineate the mechanism and better characterize the therapeutic effects of acupuncture as a treatment for TN.

4.1.2. Abortive Therapies

In addition to maintenance therapies, other drugs have been studied for use as abortive treatment during acute pain attacks. An intranasal spray of 8% lidocaine has also shown statistically significant pain reduction for four hours in patients with second-division TN [118]. Intravenous phenytoin, yet another Nav blocker, demonstrated an acute response rate of 89% in a retrospective cohort, including classic, idiopathic, and secondary TN [119]. Fosphenytoin, a prodrug of phenytoin, has similarly shown positive results in aborting TN exacerbations in small case reports [120,121].

4.2. Procedural Interventions

4.2.1. Neurological Surgeries

Microvascular decompression (MVD) is considered the first-line surgical procedure for patients with clear neurovascular compression etiology determined by imaging [122,123]. It has a well-established record of a favorable outcome, with an approximately 70% pain-free rate after the first two years post-surgery [123,124,125]. Surgical technique is also being improved over time. In a recent prospective cohort study, Mizobuchi and colleagues demonstrated complete pain relief in 80% of patients at three years follow-up, with their higher success rate attributed to transposing the causative vessel away from the trigeminal nerve with a prosthesis, rather than interposing a prosthesis between the vessel and nerve [126]. The authors in the same study also observed that an arterial compressive pattern better predicted a successful response when compared to patterns of compression due to venous structures or arachnoiditis [126].
For those without neurovascular compressions, particularly when MVD is initially intended but compression is not observed intraoperatively, open interfascicular neurolysis can be considered [127]. This technique aims to induce micro-trauma in the hyperactive trigeminal nerve by dividing the nerve longitudinally into multiple fascicles, which is thought to interrupt abnormal nociceptive transmissions and induce remyelination in the trigeminal system [127,128,129]. Although multiple retrospective studies have shown long-term symptom relief in 70–90% of the patients by this technique, the broad application of open neurolysis is limited by its invasive nature, along with the retrospective design and the small sample size of the supporting clinical studies [127,129,130,131].
Additional to the open surgical approaches, minimally invasive stereotactic radiosurgery (SRS), such as Gamma Knife and Cyberknife, which involves the application of ionizing radiation to the trigeminal nerve, is a viable alternative therapeutic option for TN. The exact mechanism of pain relief in SRS is unknown. Still, it is thought that targeted ionizing radiation damages sodium channels on the trigeminal fiber, which interrupts afferent sensory transmission [132]. Although SRS is less effective in producing lasting pain relief than MVD, it has been shown to be associated with fewer complications [133,134,135]. It also appears that SRS can be safely repeated for recurrent TN pain [136].

4.2.2. Percutaneous Techniques

When a patient cannot tolerate neurological surgery or presents without underlying vascular compression, percutaneous interventions can be offered. These techniques can be subclassified into radiofrequency thermal ablation, balloon compression, and chemical rhizotomy.
Percutaneous thermal rhizotomy with radiofrequency ablation (RFA) was first introduced by Sweet and colleagues. They hypothesized that carefully graded increments of heat could selectively damage smaller myelinated and unmyelinated fibers that are responsible for pain transmission, since the non-nociceptive A-beta fibers are relatively protected from heat due to their heavier myelin sheaths [137]. They reported a 91% rate of immediate pain relief, with a recurrence rate of 22% in patients followed over 2–6 years [137]. This finding was later confirmed by a retrospective cohort analysis of 1000 consecutive patients who underwent RFA, which showed a 94.8% immediate response rate, allowing for discontinuation of medical treatment, with an 18% recurrence rate over an average follow-up of 9 years [138]. However, 20% of patients in that study developed corneal reflex impairment, with six patients having keratitis that required surgery due to either tarsorrhaphy or enucleation [138]. RFA is also associated with an increased risk of pain recurrence and postoperative facial anesthesia compared to MVD [139]. Interestingly, it has been suggested that RFA is equally effective for patients with and without neurovascular compression, making it a viable option for those patients who are not candidates for MVD [140].
Percutaneous balloon compression (PBC) is another technique that aims to treat TN by lesioning afferent fibers at the level of the Gasserian ganglion. A recent retrospective study suggested a first-time success rate of 89% after PBC, with 76% of patients able to titrate off pain medicines [141]. Data from the past two decades support PBC as an effective therapy by showing it to be equally effective as other techniques [104,123,124,142,143,144]. Unfortunately, PBC is associated with an inconsistent recurrence rate, ranging from 19 to 59%, although repeat procedures do appear to be nearly equally efficacious [141,145]
Lastly, percutaneous glycerol rhizotomy relies on the chemical ablation of pain-transducing nerve fibers. It carries a similar success rate to other percutaneous techniques but can have a recurrence rate of up to 50% by three years post-procedure [146]. Similarly, repeat procedures have also been safe and effective [147].

5. Conclusions and Future Directions

In the past three decades, significant progress has been made to understand the pathophysiology of TN. The demyelination-induced trigeminal hyperexcitability theory has offered a critical mechanistic basis for the diagnosis and the implementation of current medical therapies (e.g., anticonvulsants, antidepressants), surgical procedures (e.g., MVD, Cyberknife, and Gamma Knife), and percutaneous techniques (e.g., RFA, PBC, glycerol rhizotomy) for TN. However, several crucial observations related to disease classification, diagnosis, and treatment efficacy have left some aspects in the current explanation of TN pathophysiology rather unsatisfying.
It has been increasingly recognized that TN’s etiology is likely multifactorial in many patients. Only a small percentage of TN patients present with demonstrable compression or morphological changes in the trigeminal nerve, and neurovascular compression does not always translate to disease [27,148,149]. Furthermore, most patients present with a normal physical and neurological exam, and there is a lack of reliable biomarkers for the disease [14,55,150,151]. Thus, such complex disease presentation makes accurate diagnosis of TN difficult for some patients and may even challenge the utility of the current classification scheme [152]. Lastly, TN often recurs with increasing resistance to therapies over time [153]. Conventionally, procedural interventions will be offered when medical therapies fail, but there is little data to guide decisions on the timing of this decision. Even though, based on a few studies, surgical and minimally invasive interventions appear to have a promising track record in providing relief, they are also known to accompany a varying degree of complications and recurrence [151].
Therefore, the lack of complete understanding of TN’s complex etiology, pathogenesis, and pathophysiology poses a challenge for clinicians and basic scientists in discovering targeted therapies for patients. Future studies focusing on investigating the basic mechanism for TN, such as genetics, molecular biology, electrophysiology, and functional imaging could further improve the precision of diagnosis and therapies for patients suffering from this debilitating disease.

Author Contributions

Conceptualization, Q.C. and X.Q.; writing—original draft preparation, Q.C., D.I.Y. and J.N.J.P.; writing—review and editing, Q.C., D.I.Y., J.N.J.P., M.L. (Monica Liu), S.D.C., M.J.B., M.L. (Michael Lim) and X.Q. All authors have read and agreed to the published version of the manuscript.

Funding

This work received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

This work was supported with resources and the use of facilities at the Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, School of Medicine (Stanford, CA, USA). The contents do not represent the views of Stanford University.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. ICHD. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018, 38, 1–211. [Google Scholar] [CrossRef] [PubMed]
  2. Mueller, D.; Obermann, M.; Yoon, M.S.; Poitz, F.; Hansen, N.; Slomke, M.A.; Dommes, P.; Gizewski, E.; Diener, H.C.; Katsarava, Z. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: A population-based study. Cephalalgia 2011, 31, 1542–1548. [Google Scholar] [CrossRef] [PubMed]
  3. Hall, G.C.; Carroll, D.; Parry, D.; McQuay, H.J. Epidemiology and treatment of neuropathic pain: The UK primary care perspective. Pain 2006, 122, 156–162. [Google Scholar] [CrossRef] [PubMed]
  4. Katusic, S.; Beard, C.M.; Bergstralh, E.; Kurland, L.T. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945–1984. Ann. Neurol. 1990, 27, 89–95. [Google Scholar] [CrossRef]
  5. Di Stefano, G.; Maarbjerg, S.; Nurmikko, T.; Truini, A.; Cruccu, G. Triggering trigeminal neuralgia. Cephalalgia 2018, 38, 1049–1056. [Google Scholar] [CrossRef]
  6. Zakrzewska, J.M.; Wu, J.; Mon-Williams, M.; Phillips, N.; Pavitt, S.H. Evaluating the impact of trigeminal neuralgia. Pain 2017, 158, 1166–1174. [Google Scholar] [CrossRef]
  7. Tan, C.Y.; Shahrizaila, N.; Goh, K.J. Clinical Characteristics, Pain, and Quality of Life Experiences of Trigeminal Neuralgia in a Multi-Ethnic Asian Cohort. J. Oral Facial Pain Headache 2017, 31, e15–e20. [Google Scholar] [CrossRef] [Green Version]
  8. Kotecha, R.; Miller, J.A.; Modugula, S.; Barnett, G.H.; Murphy, E.S.; Reddy, C.A.; Suh, J.H.; Neyman, G.; Machado, A.; Nagel, S.; et al. Stereotactic Radiosurgery for Trigeminal Neuralgia Improves Patient-Reported Quality of Life and Reduces Depression. Int. J. Radiat. Oncol. Biol. Phys. 2017, 98, 1078–1086. [Google Scholar] [CrossRef]
  9. Macianskyte, D.; Januzis, G.; Kubilius, R.; Adomaitiene, V.; Sciupokas, A. Associations between chronic pain and depressive symptoms in patients with trigeminal neuralgia. Medicina 2011, 47, 386–392. [Google Scholar] [CrossRef]
  10. Rasmussen, P. Facial pain. IV. A prospective study of 1052 patients with a view of: Precipitating factors, associated symptoms, objective psychiatric and neurological symptoms. Acta Neurochir. 1991, 108, 100–109. [Google Scholar] [CrossRef]
  11. Krafft, R.M. Trigeminal neuralgia. Am. Fam. Physician 2008, 77, 1291–1296. [Google Scholar]
  12. Lee, C.H.; Jang, H.Y.; Won, H.S.; Kim, J.S.; Kim, Y.D. Epidemiology of trigeminal neuralgia: An electronic population health data study in Korea. Korean J. Pain 2021, 34, 332–338. [Google Scholar] [CrossRef]
  13. De Toledo, I.P.; Conti Reus, J.; Fernandes, M.; Porporatti, A.L.; Peres, M.A.; Takaschima, A.; Linhares, M.N.; Guerra, E.; De Luca Canto, G. Prevalence of trigeminal neuralgia: A systematic review. J. Am. Dent. Assoc. 2016, 147, 570–576.e572. [Google Scholar] [CrossRef]
  14. Maarbjerg, S.; Gozalov, A.; Olesen, J.; Bendtsen, L. Trigeminal neuralgia—A prospective systematic study of clinical characteristics in 158 patients. Headache 2014, 54, 1574–1582. [Google Scholar] [CrossRef]
  15. Maarbjerg, S.; Gozalov, A.; Olesen, J.; Bendtsen, L. Concomitant persistent pain in classical trigeminal neuralgia—Evidence for different subtypes. Headache 2014, 54, 1173–1183. [Google Scholar] [CrossRef]
  16. El Otmani, H.; Moutaouakil, F.; Fadel, H.; Slassi, I. Familial trigeminal neuralgia. Rev. Neurol. 2008, 164, 384–387. [Google Scholar] [CrossRef]
  17. Fleetwood, I.G.; Innes, A.M.; Hansen, S.R.; Steinberg, G.K. Familial trigeminal neuralgia. Case report and review of the literature. J. Neurosurg. 2001, 95, 513–517. [Google Scholar] [CrossRef]
  18. Pareja, J.A.; Baron, M.; Gili, P.; Yanguela, J.; Caminero, A.B.; Dobato, J.L.; Barriga, F.J.; Vela, L.; Sanchez-del-Rio, M. Objective assessment of autonomic signs during triggered first division trigeminal neuralgia. Cephalalgia 2002, 22, 251–255. [Google Scholar] [CrossRef]
  19. Haviv, Y.; Khan, J.; Zini, A.; Almoznino, G.; Sharav, Y.; Benoliel, R. Trigeminal neuralgia (part I): Revisiting the clinical phenotype. Cephalalgia 2016, 36, 730–746. [Google Scholar] [CrossRef]
  20. Rasmussen, P. Facial pain. III. A prospective study of the localization of facial pain in 1052 patients. Acta Neurochir. 1991, 108, 53–63. [Google Scholar] [CrossRef]
  21. Siqueira, S.R.; Teixeira, M.J.; Siqueira, J.T. Clinical characteristics of patients with trigeminal neuralgia referred to neurosurgery. Eur. J. Dent. 2009, 3, 207–212. [Google Scholar] [CrossRef] [Green Version]
  22. Pearce, J.M. Trigeminal neuralgia (Fothergill’s disease) in the 17th and 18th centuries. J. Neurol. Neurosurg. Psychiatry 2003, 74, 1688. [Google Scholar] [CrossRef] [Green Version]
  23. Rasmussen, P. Facial pain. I. A prospective survey of 1052 patients with a view of: Definition, delimitation, classification, general data, genetic factors, and previous diseases. Acta Neurochir. 1990, 107, 112–120. [Google Scholar] [CrossRef]
  24. Shankland, W.E., 2nd. Trigeminal neuralgia: Typical or atypical? Cranio J. Craniomandib. Pract. 1993, 11, 108–112. [Google Scholar] [CrossRef]
  25. Borges, A.; Casselman, J. Imaging the trigeminal nerve. Eur. J. Radiol. 2010, 74, 323–340. [Google Scholar] [CrossRef]
  26. Hughes, M.A.; Frederickson, A.M.; Branstetter, B.F.; Zhu, X.; Sekula, R.F., Jr. MRI of the Trigeminal Nerve in Patients With Trigeminal Neuralgia Secondary to Vascular Compression. AJR Am. J. Roentgenol. 2016, 206, 595–600. [Google Scholar] [CrossRef]
  27. Antonini, G.; Di Pasquale, A.; Cruccu, G.; Truini, A.; Morino, S.; Saltelli, G.; Romano, A.; Trasimeni, G.; Vanacore, N.; Bozzao, A. Magnetic resonance imaging contribution for diagnosing symptomatic neurovascular contact in classical trigeminal neuralgia: A blinded case-control study and meta-analysis. Pain 2014, 155, 1464–1471. [Google Scholar] [CrossRef]
  28. Chen, D.Q.; DeSouza, D.D.; Hayes, D.J.; Davis, K.D.; O’Connor, P.; Hodaie, M. Diffusivity signatures characterize trigeminal neuralgia associated with multiple sclerosis. Mult. Scler. 2016, 22, 51–63. [Google Scholar] [CrossRef] [Green Version]
  29. Cruccu, G.; Biasiotta, A.; Di Rezze, S.; Fiorelli, M.; Galeotti, F.; Innocenti, P.; Mameli, S.; Millefiorini, E.; Truini, A. Trigeminal neuralgia and pain related to multiple sclerosis. Pain 2009, 143, 186–191. [Google Scholar] [CrossRef]
  30. Love, S.; Gradidge, T.; Coakham, H.B. Trigeminal neuralgia due to multiple sclerosis: Ultrastructural findings in trigeminal rhizotomy specimens. Neuropathol. Appl. Neurobiol. 2001, 27, 238–244. [Google Scholar] [CrossRef]
  31. Ravichandran, A.; Elsayed, K.S.; Yacoub, H.A. Central Pain Mimicking Trigeminal Neuralgia as a Result of Lateral Medullary Ischemic Stroke. Case Rep. Neurol. Med. 2019, 2019, 4235724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Benoliel, R.; Svensson, P.; Evers, S.; Wang, S.J.; Barke, A.; Korwisi, B.; Rief, W.; Treede, R.D.; The IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: Chronic secondary headache or orofacial pain. Pain 2019, 160, 60–68. [Google Scholar] [CrossRef] [PubMed]
  33. Scholz, J.; Finnerup, N.B.; Attal, N.; Aziz, Q.; Baron, R.; Bennett, M.I.; Benoliel, R.; Cohen, M.; Cruccu, G.; Davis, K.D.; et al. The IASP classification of chronic pain for ICD-11: Chronic neuropathic pain. Pain 2019, 160, 53–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Eller, J.L.; Raslan, A.M.; Burchiel, K.J. Trigeminal neuralgia: Definition and classification. Neurosurg. Focus 2005, 18, E3. [Google Scholar] [CrossRef]
  35. Burchiel, K.J. A new classification for facial pain. Neurosurgery 2003, 53, 1164–1166; discussion 1166–1167. [Google Scholar] [CrossRef]
  36. Jones, M.R.; Urits, I.; Ehrhardt, K.P.; Cefalu, J.N.; Kendrick, J.B.; Park, D.J.; Cornett, E.M.; Kaye, A.D.; Viswanath, O. A Comprehensive Review of Trigeminal Neuralgia. Curr. Pain Headache Rep. 2019, 23, 74. [Google Scholar] [CrossRef]
  37. Haines, S.J.; Jannetta, P.J.; Zorub, D.S. Microvascular relations of the trigeminal nerve. An anatomical study with clinical correlation. J. Neurosurg. 1980, 52, 381–386. [Google Scholar] [CrossRef]
  38. Chen, J.; Guo, Z.Y.; Liang, Q.Z.; Liao, H.Y.; Su, W.R.; Chen, C.X.; Fu, S.X.; Han, X.J. Structural abnormalities of trigeminal root with neurovascular compression revealed by high resolution diffusion tensor imaging. Asian Pac. J. Trop. Med. 2012, 5, 749–752. [Google Scholar] [CrossRef]
  39. Richards, P.; Shawdon, H.; Illingworth, R. Operative findings on microsurgical exploration of the cerebello-pontine angle in trigeminal neuralgia. J. Neurol. Neurosurg. Psychiatry 1983, 46, 1098–1101. [Google Scholar] [CrossRef] [Green Version]
  40. Bowsher, D. Trigeminal neuralgia: An anatomically oriented review. Clin. Anat. 1997, 10, 409–415. [Google Scholar] [CrossRef]
  41. Montano, N.; Conforti, G.; Di Bonaventura, R.; Meglio, M.; Fernandez, E.; Papacci, F. Advances in diagnosis and treatment of trigeminal neuralgia. Clin. Risk Manag. 2015, 11, 289–299. [Google Scholar] [CrossRef] [Green Version]
  42. Peker, S.; Kurtkaya, O.; Uzun, I.; Pamir, M.N. Microanatomy of the central myelin-peripheral myelin transition zone of the trigeminal nerve. Neurosurgery 2006, 59, 354–359. [Google Scholar] [CrossRef]
  43. Kerr, F.W.; Miller, R.H. The pathology of trigeminal neuralgia. Electron microscopic studies. Arch. Neurol. 1966, 15, 308–319. [Google Scholar] [CrossRef]
  44. Beaver, D.L. Electron microscopy of the gasserian ganglion in trigeminal neuralgia. J. Neurosurg. 1967, 26, 138–150. [Google Scholar] [CrossRef]
  45. Hilton, D.A.; Love, S.; Gradidge, T.; Coakham, H.B. Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery 1994, 35, 299–303. [Google Scholar] [CrossRef]
  46. Love, S.; Hilton, D.A.; Coakham, H.B. Central demyelination of the Vth nerve root in trigeminal neuralgia associated with vascular compression. Brain Pathol 1998, 8, 1–11. [Google Scholar] [CrossRef]
  47. Prasad, S.; Galetta, S. Trigeminal neuralgia: Historical notes and current concepts. Neurologist 2009, 15, 87–94. [Google Scholar] [CrossRef]
  48. Gupta, R.; Rowshan, K.; Chao, T.; Mozaffar, T.; Steward, O. Chronic nerve compression induces local demyelination and remyelination in a rat model of carpal tunnel syndrome. Exp. Neurol. 2004, 187, 500–508. [Google Scholar] [CrossRef]
  49. Gupta, R.; Steward, O. Chronic nerve compression induces concurrent apoptosis and proliferation of Schwann cells. J. Comp. Neurol. 2003, 461, 174–186. [Google Scholar] [CrossRef]
  50. Pham, K.; Gupta, R. Understanding the mechanisms of entrapment neuropathies. Review article. Neurosurg. Focus 2009, 26, E7. [Google Scholar] [CrossRef]
  51. Mackinnon, S.E.; Dellon, A.L.; Hudson, A.R.; Hunter, D.A. Chronic human nerve compression—A histological assessment. Neuropathol. Appl. Neurobiol. 1986, 12, 547–565. [Google Scholar] [CrossRef]
  52. Berger, B.L.; Gupta, R. Demyelination secondary to chronic nerve compression injury alters Schmidt-Lanterman incisures. J. Anat. 2006, 209, 111–118. [Google Scholar] [CrossRef]
  53. Devor, M.; Govrin-Lippmann, R.; Rappaport, Z.H. Mechanism of trigeminal neuralgia: An ultrastructural analysis of trigeminal root specimens obtained during microvascular decompression surgery. J. Neurosurg. 2002, 96, 532–543. [Google Scholar] [CrossRef] [Green Version]
  54. Marinkovic, S.; Gibo, H.; Todorovic, V.; Antic, B.; Kovacevic, D.; Milisavljevic, M.; Cetkovic, M. Ultrastructure and immunohistochemistry of the trigeminal peripheral myelinated axons in patients with neuralgia. Clin. Neurol. Neurosurg. 2009, 111, 795–800. [Google Scholar] [CrossRef]
  55. Maarbjerg, S.; Di Stefano, G.; Bendtsen, L.; Cruccu, G. Trigeminal neuralgia-diagnosis and treatment. Cephalalgia 2017, 37, 648–657. [Google Scholar] [CrossRef]
  56. Leal, P.R.; Barbier, C.; Hermier, M.; Souza, M.A.; Cristino-Filho, G.; Sindou, M. Atrophic changes in the trigeminal nerves of patients with trigeminal neuralgia due to neurovascular compression and their association with the severity of compression and clinical outcomes. J. Neurosurg. 2014, 120, 1484–1495. [Google Scholar] [CrossRef]
  57. Gambeta, E.; Chichorro, J.G.; Zamponi, G.W. Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments. Mol. Pain 2020, 16, 1744806920901890. [Google Scholar] [CrossRef] [Green Version]
  58. Liu, M.; Zhong, J.; Xia, L.; Dou, N.; Li, S. The expression of voltage-gated sodium channels in trigeminal nerve following chronic constriction injury in rats. Int. J. Neurosci. 2019, 129, 955–962. [Google Scholar] [CrossRef]
  59. Xu, W.; Zhang, J.; Wang, Y.; Wang, L.; Wang, X. Changes in the expression of voltage-gated sodium channels Nav1.3, Nav1.7, Nav1.8, and Nav1.9 in rat trigeminal ganglia following chronic constriction injury. Neuroreport 2016, 27, 929–934. [Google Scholar] [CrossRef]
  60. Siqueira, S.R.; Alves, B.; Malpartida, H.M.; Teixeira, M.J.; Siqueira, J.T. Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia. Neuroscience 2009, 164, 573–577. [Google Scholar] [CrossRef]
  61. Abe, M.; Kurihara, T.; Han, W.; Shinomiya, K.; Tanabe, T. Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. Spine 2002, 27, 1517–1524. [Google Scholar] [CrossRef] [PubMed]
  62. Dib-Hajj, S.D.; Fjell, J.; Cummins, T.R.; Zheng, Z.; Fried, K.; LaMotte, R.; Black, J.A.; Waxman, S.G. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999, 83, 591–600. [Google Scholar] [CrossRef]
  63. Lampert, A.; Hains, B.C.; Waxman, S.G. Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury. Exp. Brain Res. 2006, 174, 660–666. [Google Scholar] [CrossRef] [PubMed]
  64. Dib-Hajj, S.D.; Cummins, T.R.; Black, J.A.; Waxman, S.G. From genes to pain: Na v 1.7 and human pain disorders. Trends Neurosci. 2007, 30, 555–563. [Google Scholar] [CrossRef] [PubMed]
  65. Pineda-Farias, J.B.; Loeza-Alcocer, E.; Nagarajan, V.; Gold, M.S.; Sekula, R.F., Jr. Mechanisms Underlying the Selective Therapeutic Efficacy of Carbamazepine for Attenuation of Trigeminal Nerve Injury Pain. J. Neurosci. 2021, 41, 8991–9007. [Google Scholar] [CrossRef] [PubMed]
  66. Abd-Elsayed, A.A.; Ikeda, R.; Jia, Z.; Ling, J.; Zuo, X.; Li, M.; Gu, J.G. KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia. Mol. Pain 2015, 11, 45. [Google Scholar] [CrossRef] [Green Version]
  67. Gupta, R.; Rummler, L.S.; Palispis, W.; Truong, L.; Chao, T.; Rowshan, K.; Mozaffar, T.; Steward, O. Local down-regulation of myelin-associated glycoprotein permits axonal sprouting with chronic nerve compression injury. Exp. Neurol. 2006, 200, 418–429. [Google Scholar] [CrossRef]
  68. Cheng, J.; Meng, J.; Liu, W.; Zhang, H.; Lei, D.; Hui, X. Nerve Atrophy and a Small Trigeminal Pontine Angle in Primary Trigeminal Neuralgia: A Morphometric Magnetic Resonance Imaging Study. World Neurosurg. 2017, 104, 575–580. [Google Scholar] [CrossRef]
  69. Roccuzzo, A.; Molinero-Mourelle, P.; Ferrillo, M.; Cobo-Vázquez, C.; Sanchez-Labrador, L.; Ammendolia, A.; Migliario, M.; de Sire, A. Type I Collagen-Based Devices to Treat Nerve Injuries after Oral Surgery Procedures. A Systematic Review. Appl. Sci. 2021, 11, 3927. [Google Scholar] [CrossRef]
  70. Burchiel, K.J. Abnormal impulse generation in focally demyelinated trigeminal roots. J. Neurosurg. 1980, 53, 674–683. [Google Scholar] [CrossRef]
  71. Calvin, W.H.; Loeser, J.D.; Howe, J.F. A neurophysiological theory for the pain mechanism of tic douloureux. Pain 1977, 3, 147–154. [Google Scholar] [CrossRef]
  72. Puil, E.; Spigelman, I. Electrophysiological responses of trigeminal root ganglion neurons in vitro. Neuroscience 1988, 24, 635–646. [Google Scholar] [CrossRef]
  73. Rappaport, H.Z.; Devor, M. Trigeminal neuralgia: The role of self-sustaining discharge in the trigeminal ganglion. Pain 1994, 56, 127–138. [Google Scholar] [CrossRef]
  74. Love, S.; Coakham, H.B. Trigeminal neuralgia: Pathology and pathogenesis. Brain 2001, 124, 2347–2360. [Google Scholar] [CrossRef] [Green Version]
  75. Devor, M.; Seltzer, Z.; Wall, P.; Melzack, R. Pathophysiology of Damaged Nerves in Relation to Chronic Pain; Churchill Livingstone: London, UK, 1999; pp. 129–164. [Google Scholar]
  76. Rasminsky, M. Ectopic generation of impulses and cross-talk in spinal nerve roots of “dystrophic” mice. Ann. Neurol. 1978, 3, 351–357. [Google Scholar] [CrossRef]
  77. Amir, R.; Devor, M. Functional cross-excitation between afferent A- and C-neurons in dorsal root ganglia. Neuroscience 2000, 95, 189–195. [Google Scholar] [CrossRef]
  78. Devor, M.; Amir, R.; Rappaport, Z.H. Pathophysiology of trigeminal neuralgia: The ignition hypothesis. Clin. J. Pain 2002, 18, 4–13. [Google Scholar] [CrossRef]
  79. Katusic, S.; Williams, D.B.; Beard, C.M.; Bergstralh, E.J.; Kurland, L.T. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: Similarities and differences, Rochester, Minnesota, 1945–1984. Neuroepidemiology 1991, 10, 276–281. [Google Scholar] [CrossRef]
  80. Foley, P.L.; Vesterinen, H.M.; Laird, B.J.; Sena, E.S.; Colvin, L.A.; Chandran, S.; MacLeod, M.R.; Fallon, M.T. Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis. Pain 2013, 154, 632–642. [Google Scholar] [CrossRef]
  81. da Silva, C.J.; da Rocha, A.J.; Mendes, M.F.; Maia, A.C., Jr.; Braga, F.T.; Tilbery, C.P. Trigeminal involvement in multiple sclerosis: Magnetic resonance imaging findings with clinical correlation in a series of patients. Mult. Scler. 2005, 11, 282–285. [Google Scholar] [CrossRef]
  82. Olafson, R.A.; Rushton, J.G.; Sayre, G.P. Trigeminal neuralgia in a patient with multiple sclerosis. An autopsy report. J. Neurosurg. 1966, 24, 755–759. [Google Scholar] [CrossRef]
  83. Di Stefano, G.; Maarbjerg, S.; Truini, A. Trigeminal neuralgia secondary to multiple sclerosis: From the clinical picture to the treatment options. J. Headache Pain 2019, 20, 20. [Google Scholar] [CrossRef] [Green Version]
  84. Truini, A.; Prosperini, L.; Calistri, V.; Fiorelli, M.; Pozzilli, C.; Millefiorini, E.; Frontoni, M.; Cortese, A.; Caramia, F.; Cruccu, G. A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology 2016, 86, 2094–2099. [Google Scholar] [CrossRef]
  85. Nakashima, I.; Fujihara, K.; Kimpara, T.; Okita, N.; Takase, S.; Itoyama, Y. Linear pontine trigeminal root lesions in multiple sclerosis: Clinical and magnetic resonance imaging studies in 5 cases. Arch. Neurol. 2001, 58, 101–104. [Google Scholar] [CrossRef] [Green Version]
  86. Laakso, S.M.; Hekali, O.; Kurdo, G.; Martola, J.; Sairanen, T.; Atula, S. Trigeminal neuralgia in multiple sclerosis: Prevalence and association with demyelination. Acta Neurol. Scand. 2020, 142, 139–144. [Google Scholar] [CrossRef]
  87. Tohyama, S.; Hung, P.S.; Cheng, J.C.; Zhang, J.Y.; Halawani, A.; Mikulis, D.J.; Oh, J.; Hodaie, M. Trigeminal neuralgia associated with a solitary pontine lesion: Clinical and neuroimaging definition of a new syndrome. Pain 2020, 161, 916–925. [Google Scholar] [CrossRef]
  88. Neetu, S.; Sunil, K.; Ashish, A.; Jayantee, K.; Usha Kant, M. Microstructural abnormalities of the trigeminal nerve by diffusion-tensor imaging in trigeminal neuralgia without neurovascular compression. Neuroradiol. J. 2016, 29, 13–18. [Google Scholar] [CrossRef] [Green Version]
  89. Lummel, N.; Mehrkens, J.H.; Linn, J.; Buchholz, G.; Stahl, R.; Bochmann, K.; Bruckmann, H.; Lutz, J. Diffusion tensor imaging of the trigeminal nerve in patients with trigeminal neuralgia due to multiple sclerosis. Neuroradiology 2015, 57, 259–267. [Google Scholar] [CrossRef]
  90. Peker, S.; Akansel, G.; Sun, I.; Pamir, N.M. Trigeminal neuralgia due to pontine infarction. Headache 2004, 44, 1043–1045. [Google Scholar] [CrossRef]
  91. Noory, N.; Smilkov, E.A.; Frederiksen, J.L.; Heinskou, T.B.; Andersen, A.S.S.; Bendtsen, L.; Maarbjerg, S. Neurovascular contact plays no role in trigeminal neuralgia secondary to multiple sclerosis. Cephalalgia 2021, 41, 593–603. [Google Scholar] [CrossRef]
  92. Cruccu, G.; Biasiotta, A.; Galeotti, F.; Iannetti, G.D.; Truini, A.; Gronseth, G. Diagnostic accuracy of trigeminal reflex testing in trigeminal neuralgia. Neurology 2006, 66, 139–141. [Google Scholar] [CrossRef] [PubMed]
  93. Latremoliere, A.; Woolf, C.J. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. J. Pain 2009, 10, 895–926. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Woolf, C.J. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011, 152, S2–S15. [Google Scholar] [CrossRef] [PubMed]
  95. Obermann, M.; Yoon, M.S.; Ese, D.; Maschke, M.; Kaube, H.; Diener, H.C.; Katsarava, Z. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology 2007, 69, 835–841. [Google Scholar] [CrossRef]
  96. Moisset, X.; Villain, N.; Ducreux, D.; Serrie, A.; Cunin, G.; Valade, D.; Calvino, B.; Bouhassira, D. Functional brain imaging of trigeminal neuralgia. Eur. J. Pain 2011, 15, 124–131. [Google Scholar] [CrossRef]
  97. Zhang, C.; Hu, H.; Das, S.K.; Yang, M.J.; Li, B.; Li, Y.; Xu, X.X.; Yang, H.F. Structural and Functional Brain Abnormalities in Trigeminal Neuralgia: A Systematic Review. J. Oral Facial Pain Headache 2020, 34, 222–235. [Google Scholar] [CrossRef]
  98. Ji, R.R.; Kohno, T.; Moore, K.A.; Woolf, C.J. Central sensitization and LTP: Do pain and memory share similar mechanisms? Trends Neurosci. 2003, 26, 696–705. [Google Scholar] [CrossRef]
  99. Neblett, R.; Cohen, H.; Choi, Y.; Hartzell, M.M.; Williams, M.; Mayer, T.G.; Gatchel, R.J. The Central Sensitization Inventory (CSI): Establishing Clinically Significant Values for Identifying Central Sensitivity Syndromes in an Outpatient Chronic Pain Sample. J. Pain 2013, 14, 438–445. [Google Scholar] [CrossRef] [Green Version]
  100. Tang, Y.; Wang, M.; Zheng, T.; Yuan, F.; Yang, H.; Han, F.; Chen, G. Grey matter volume alterations in trigeminal neuralgia: A systematic review and meta-analysis of voxel-based morphometry studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 2020, 98, 109821. [Google Scholar] [CrossRef]
  101. Nicol, C.F. A four year double-blind study of tegretol in facial pain. Headache 1969, 9, 54–57. [Google Scholar] [CrossRef]
  102. Killian, J.M.; Fromm, G.H. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 1968, 19, 129–136. [Google Scholar] [CrossRef]
  103. Campbell, F.G.; Graham, J.G.; Zilkha, K.J. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J. Neurol. Neurosurg. Psychiatry 1966, 29, 265–267. [Google Scholar] [CrossRef] [Green Version]
  104. Bendtsen, L.; Zakrzewska, J.M.; Abbott, J.; Braschinsky, M.; Di Stefano, G.; Donnet, A.; Eide, P.K.; Leal, P.R.L.; Maarbjerg, S.; May, A.; et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur. J. Neurol. 2019, 26, 831–849. [Google Scholar] [CrossRef] [Green Version]
  105. Di Stefano, G.; De Stefano, G.; Leone, C.; Di Lionardo, A.; Di Pietro, G.; Sgro, E.; Mollica, C.; Cruccu, G.; Truini, A. Real-world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia. Eur. J. Pain 2021, 25, 1064–1071. [Google Scholar] [CrossRef]
  106. Zakrzewska, J.M.; Chaudhry, Z.; Nurmikko, T.J.; Patton, D.W.; Mullens, L.E. Lamotrigine (lamictal) in refractory trigeminal neuralgia: Results from a double-blind placebo controlled crossover trial. Pain 1997, 73, 223–230. [Google Scholar] [CrossRef]
  107. Yuan, M.; Zhou, H.Y.; Xiao, Z.L.; Wang, W.; Li, X.L.; Chen, S.J.; Yin, X.P.; Xu, L.J. Efficacy and Safety of Gabapentin vs. Carbamazepine in the Treatment of Trigeminal Neuralgia: A Meta-Analysis. Pain Pract. 2016, 16, 1083–1091. [Google Scholar] [CrossRef]
  108. Lemos, L.; Flores, S.; Oliveira, P.; Almeida, A. Gabapentin supplemented with ropivacain block of trigger points improves pain control and quality of life in trigeminal neuralgia patients when compared with gabapentin alone. Clin. J. Pain 2008, 24, 64–75. [Google Scholar] [CrossRef] [Green Version]
  109. Zhang, H.; Lian, Y.; Ma, Y.; Chen, Y.; He, C.; Xie, N.; Wu, C. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J. Headache Pain 2014, 15, 65. [Google Scholar] [CrossRef] [Green Version]
  110. Zuniga, C.; Piedimonte, F.; Diaz, S.; Micheli, F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin. Neuropharmacol. 2013, 36, 146–150. [Google Scholar] [CrossRef]
  111. Wu, C.J.; Lian, Y.J.; Zheng, Y.K.; Zhang, H.F.; Chen, Y.; Xie, N.C.; Wang, L.J. Botulinum toxin type A for the treatment of trigeminal neuralgia: Results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012, 32, 443–450. [Google Scholar] [CrossRef]
  112. Rubis, A.; Juodzbalys, G. The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: A Systematic Literature Review. J. Oral Maxillofac. Res. 2020, 11, e2. [Google Scholar] [CrossRef]
  113. Shin, M.C.; Wakita, M.; Xie, D.J.; Yamaga, T.; Iwata, S.; Torii, Y.; Harakawa, T.; Ginnaga, A.; Kozaki, S.; Akaike, N. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J. Pharm. Sci. 2012, 118, 33–42. [Google Scholar] [CrossRef] [Green Version]
  114. Xia, J.H.; He, C.H.; Zhang, H.F.; Lian, Y.J.; Chen, Y.; Wu, C.J.; Ma, Y.Q. Botulinum toxin A in the treatment of trigeminal neuralgia. Int. J. Neurosci. 2016, 126, 348–353. [Google Scholar] [CrossRef]
  115. Ernst, E. Acupuncture—A critical analysis. J. Intern. Med. 2006, 259, 125–137. [Google Scholar] [CrossRef]
  116. Sun, J.; Li, R.; Li, X.; Chen, L.; Liang, Y.; Zhang, Q.; Sun, R.; Hu, H.; Shao, X.; Fang, J. Electroacupuncture therapy for change of pain in classical trigeminal neuralgia. Medicine 2020, 99, e19710. [Google Scholar] [CrossRef] [PubMed]
  117. Hu, H.; Chen, L.; Ma, R.; Gao, H.; Fang, J. Acupuncture for primary trigeminal neuralgia: A systematic review and PRISMA-compliant meta-analysis. Complement. Clin. Pract. 2019, 34, 254–267. [Google Scholar] [CrossRef] [PubMed]
  118. Kanai, A.; Suzuki, A.; Kobayashi, M.; Hoka, S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br. J. Anaesth. 2006, 97, 559–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  119. Schnell, S.; Marrodan, M.; Acosta, J.N.; Bonamico, L.; Goicochea, M.T. Trigeminal Neuralgia Crisis—Intravenous Phenytoin as Acute Rescue Treatment. Headache 2020, 60, 2247–2253. [Google Scholar] [CrossRef] [PubMed]
  120. Vargas, A.; Thomas, K. Intravenous fosphenytoin for acute exacerbation of trigeminal neuralgia: Case report and literature review. Adv. Neurol. Disord. 2015, 8, 187–188. [Google Scholar] [CrossRef] [Green Version]
  121. Cheshire, W.P. Fosphenytoin: An intravenous option for the management of acute trigeminal neuralgia crisis. J. Pain Symptom. Manag. 2001, 21, 506–510. [Google Scholar] [CrossRef]
  122. Cruccu, G.; Gronseth, G.; Alksne, J.; Argoff, C.; Brainin, M.; Burchiel, K.; Nurmikko, T.; Zakrzewska, J.M.; American Academy of Neurology, S.; European Federation of Neurological, S. AAN-EFNS guidelines on trigeminal neuralgia management. Eur. J. Neurol. 2008, 15, 1013–1028. [Google Scholar] [CrossRef]
  123. Cruccu, G.; Di Stefano, G.; Truini, A. Trigeminal Neuralgia. New Engl. J. Med. 2020, 383, 754–762. [Google Scholar] [CrossRef]
  124. Tatli, M.; Satici, O.; Kanpolat, Y.; Sindou, M. Various surgical modalities for trigeminal neuralgia: Literature study of respective long-term outcomes. Acta Neurochir. 2008, 150, 243–255. [Google Scholar] [CrossRef]
  125. Holste, K.; Chan, A.Y.; Rolston, J.D.; Englot, D.J. Pain Outcomes Following Microvascular Decompression for Drug-Resistant Trigeminal Neuralgia: A Systematic Review and Meta-Analysis. Neurosurgery 2020, 86, 182–190. [Google Scholar] [CrossRef]
  126. Mizobuchi, Y.; Nagahiro, S.; Kondo, A.; Arita, K.; Date, I.; Fujii, Y.; Fujimaki, T.; Hanaya, R.; Hasegawa, M.; Hatayama, T.; et al. Microvascular Decompression for Trigeminal Neuralgia: A Prospective, Multicenter Study. Neurosurgery 2021, 89, 557–564. [Google Scholar] [CrossRef]
  127. Ma, Z.; Li, M. "Nerve combing" for trigeminal neuralgia without vascular compression: Report of 10 cases. Clin. J. Pain 2009, 25, 44–47. [Google Scholar] [CrossRef]
  128. Ferroli, P.; Vetrano, I.G.; Acerbi, F.; Raccuia, G.; Schiariti, M.; Confalonieri, P.; Chiapparini, L.; Broggi, M. Trigeminal interfascicular neurolysis (nerve combing) for refractory recurrent neuralgia in multiple sclerosis. Neurosurg. Focus Video FOCVID 2020, 3, V3. [Google Scholar] [CrossRef]
  129. Li, M.W.; Jiang, X.F.; Niu, C. Efficacy of Internal Neurolysis for Trigeminal Neuralgia without Vascular Compression. J. Neurol. Surg. A Cent. Eur. Neurosurg. 2021, 82, 364–368. [Google Scholar] [CrossRef]
  130. Zhao, H.; Zhang, X.; Tang, D.; Li, S. Nerve Combing for Trigeminal Neuralgia Without Vascular Compression. J. Craniofac. Surg. 2017, 28, e15–e16. [Google Scholar] [CrossRef]
  131. Jie, H.; Xuanchen, Z.; Deheng, L.; Kun, G.; Fengyang, X.; Xiang, C.; Xiaoting, W.; Guangxin, Z.; Yiqing, L. The long-term outcome of nerve combing for trigeminal neuralgia. Acta Neurochir. 2013, 155, 1703–1708, discussion 1707. [Google Scholar] [CrossRef]
  132. Gorgulho, A. Radiation mechanisms of pain control in classical trigeminal neuralgia. Surg. Neurol. Int. 2012, 3, S17–S25. [Google Scholar] [CrossRef]
  133. Zeng, Y.J.; Zhang, H.; Yu, S.; Zhang, W.; Sun, X.C. Efficacy and Safety of Microvascular Decompression and Gamma Knife Surgery Treatments for Patients with Primary Trigeminal Neuralgia: A Prospective Study. World Neurosurg. 2018, 116, e113–e117. [Google Scholar] [CrossRef]
  134. Brisman, R. Microvascular decompression vs. gamma knife radiosurgery for typical trigeminal neuralgia: Preliminary findings. Stereotact. Funct. Neurosurg. 2007, 85, 94–98. [Google Scholar] [CrossRef]
  135. Romanelli, P.; Conti, A.; Redaelli, I.; Martinotti, A.S.; Bergantin, A.; Bianchi, L.C.; Beltramo, G. Cyberknife Radiosurgery for Trigeminal Neuralgia. Cureus 2019, 11, e6014. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  136. Tuleasca, C.; Carron, R.; Resseguier, N.; Donnet, A.; Roussel, P.; Gaudart, J.; Levivier, M.; Regis, J. Repeat Gamma Knife surgery for recurrent trigeminal neuralgia: Long-term outcomes and systematic review. J. Neurosurg. 2014, 121, 210–221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  137. Sweet, W.H.; Wepsic, J.G. Controlled thermocoagulation of trigeminal ganglion and rootlets for differential destruction of pain fibers. 1. Trigeminal neuralgia. J. Neurosurg. 1974, 40, 143–156. [Google Scholar] [CrossRef] [PubMed]
  138. Broggi, G.; Franzini, A.; Lasio, G.; Giorgi, C.; Servello, D. Long-term results of percutaneous retrogasserian thermorhizotomy for “essential” trigeminal neuralgia: Considerations in 1000 consecutive patients. Neurosurgery 1990, 26, 783–786. [Google Scholar] [CrossRef] [PubMed]
  139. Yan, C.; Zhang, Q.; Liu, C.; Yang, J.; Bian, H.; Zhu, J.; Xue, T. Efficacy and safety of radiofrequency in the treatment of trigeminal neuralgia: A systematic review and meta-analysis. Acta Neurol. Belg. 2021, 1–12. [Google Scholar] [CrossRef] [PubMed]
  140. Kao, C.H.; Lee, M.H.; Yang, J.T.; Tsai, Y.H.; Lin, M.H. Percutaneous Radiofrequency Rhizotomy Is Equally Effective for Trigeminal Neuralgia Patients with or without Neurovascular Compression. Pain Med. 2021. [Google Scholar] [CrossRef]
  141. Grewal, S.S.; Kerezoudis, P.; Garcia, O.; Quinones-Hinojosa, A.; Reimer, R.; Wharen, R.E. Results of Percutaneous Balloon Compression in Trigeminal Pain Syndromes. World Neurosurg. 2018, 114, e892–e899. [Google Scholar] [CrossRef]
  142. Sterman-Neto, H.; Fukuda, C.Y.; Duarte, K.P.; Aparecida da Silva, V.; Rodrigues, A.L.L.; Galhardoni, R.; de Siqueira, S.; de Siqueira, J.T.T.; Teixeira, M.J.; Ciampi de Andrade, D. Balloon compression vs radiofrequency for primary trigeminal neuralgia: A randomized, controlled trial. Pain 2021, 162, 919–929. [Google Scholar] [CrossRef]
  143. Texakalidis, P.; Xenos, D.; Tora, M.S.; Wetzel, J.S.; Boulis, N.M. Comparative safety and efficacy of percutaneous approaches for the treatment of trigeminal neuralgia: A systematic review and meta-analysis. Clin. Neurol. Neurosurg. 2019, 182, 112–122. [Google Scholar] [CrossRef]
  144. Huang, B.; Yao, M.; Chen, Q.; Du, X.; Li, Z.; Xie, K.; Fei, Y.; Do, H.; Qian, X. Efficacy and Safety of Awake Computed Tomography-Guided Percutaneous Balloon Compression of Trigeminal Ganglion for Trigeminal Neuralgia. Pain Med. 2021, 22, 2700–2707. [Google Scholar] [CrossRef]
  145. Skirving, D.J.; Dan, N.G. A 20-year review of percutaneous balloon compression of the trigeminal ganglion. J. Neurosurg. 2001, 94, 913–917. [Google Scholar] [CrossRef]
  146. Lopez, B.C.; Hamlyn, P.J.; Zakrzewska, J.M. Systematic review of ablative neurosurgical techniques for the treatment of trigeminal neuralgia. Neurosurgery 2004, 54, 973–982. [Google Scholar] [CrossRef]
  147. Harries, A.M.; Mitchell, R.D. Percutaneous glycerol rhizotomy for trigeminal neuralgia: Safety and efficacy of repeat procedures. Br. J. Neurosurg. 2011, 25, 268–272. [Google Scholar] [CrossRef]
  148. Maarbjerg, S.; Wolfram, F.; Gozalov, A.; Olesen, J.; Bendtsen, L. Significance of neurovascular contact in classical trigeminal neuralgia. Brain 2015, 138, 311–319. [Google Scholar] [CrossRef] [Green Version]
  149. Ko, A.L.; Lee, A.; Raslan, A.M.; Ozpinar, A.; McCartney, S.; Burchiel, K.J. Trigeminal neuralgia without neurovascular compression presents earlier than trigeminal neuralgia with neurovascular compression. J. Neurosurg. 2015, 123, 1519–1527. [Google Scholar] [CrossRef]
  150. Cruccu, G.; Finnerup, N.B.; Jensen, T.S.; Scholz, J.; Sindou, M.; Svensson, P.; Treede, R.D.; Zakrzewska, J.M.; Nurmikko, T. Trigeminal neuralgia: New classification and diagnostic grading for practice and research. Neurology 2016, 87, 220–228. [Google Scholar] [CrossRef]
  151. Lambru, G.; Zakrzewska, J.; Matharu, M. Trigeminal neuralgia: A practical guide. Pract. Neurol. 2021, 21, 392–402. [Google Scholar] [CrossRef]
  152. Zakrzewska, J.M. Classification issues related to neuropathic trigeminal pain. J. Orofac. Pain 2004, 18, 325–331. [Google Scholar]
  153. O’Callaghan, L.; Floden, L.; Vinikoor-Imler, L.; Symonds, T.; Giblin, K.; Hartford, C.; Zakrzewska, J.M. Burden of illness of trigeminal neuralgia among patients managed in a specialist center in England. J. Headache Pain 2020, 21, 130. [Google Scholar] [CrossRef]
Table
Table 1. Comparison of TN Classifications.
Table 1. Comparison of TN Classifications.
ClassificationsICHD-3/IASPTypical vs. Atypical TN by RasmussenBurchiel Classifications
CharacteristicThe classification was developed based on consensus between the International Headache Society (IHS) and the International Association for the Study of Pain (IASP) to create a classification of TN that is more universally accepted among clinicians and academics.The first classification that attempted to further subclassify TN based on its attack characteristics in 1990The classification by Burchiel et al. categorized seven types of TN based on the pain characteristic or its associated eliciting event in order to provide a framework to better diagnose and treat different types of TN.
Subclassifications- Classical TN *—typical symptomatic TN due to neurovascular compression of trigeminal nerve evidenced by imaging (MRI) or surgery
- Secondary TN—typical symptomatic TN caused by an underlying disease, other than the neurovascular compression, which includes Multiple Sclerosis, space-occupying lesions including cerebellopontine angle, AV malformation or fistula, skull-base bone deformity, connective tissue disease, and genetic causes of neuropathy
- Idiopathic TN *—symptomatic TN with neither MRI nor electrophysiological tests revealing significant abnormalities, suggesting TN without obvious or visible etiologies that are not fully understood yet
* Classical and Idiopathic TN are also sub-categorized as “purely paroxysmal” or “with concomitant continuous pain” in an effort to address the timing of pain attacks.		- Typical TN: pain described as sharp, electrical, paroxysmal, and mostly located in the V2 and V3 regions of the trigeminal nerve
- Atypical TN: pain described as dull, constant, and located in all 3 divisions		- TN type I—sharp, electrical shock-like, episodic pain due to neurovascular compression of TN
- TN type II—aching, throbbing, burning, constant pain >50% of the time
- TN due to injury—Trigeminal neuropathic pain (unintentional) e.g., facial trauma
- Trigeminal deafferentation pain (intentional) e.g., post-surgical
- TN secondary to multiple sclerosis
- Infection-related postherpetic TN
- Atypical somatoform facial pain
Comments- Most recent classification for TN (published in 2018)
- Requires imaging and/or electrophysiological findings for subclassification diagnosis
- Helps guide further treatment modalities (medical vs. surgical)		- This classification was too broad to guide specific treatment based on symptoms alone.- This classification attempts to guide differential diagnosis by using objective and reproducible criteria.
- Requires further studies to verify clinical utility
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Chen, Q.; Yi, D.I.; Perez, J.N.J.; Liu, M.; Chang, S.D.; Barad, M.J.; Lim, M.; Qian, X. The Molecular Basis and Pathophysiology of Trigeminal Neuralgia. Int. J. Mol. Sci. 2022, 23, 3604. https://doi.org/10.3390/ijms23073604

AMA Style

Chen Q, Yi DI, Perez JNJ, Liu M, Chang SD, Barad MJ, Lim M, Qian X. The Molecular Basis and Pathophysiology of Trigeminal Neuralgia. International Journal of Molecular Sciences. 2022; 23(7):3604. https://doi.org/10.3390/ijms23073604

Chicago/Turabian Style

Chen, QiLiang, Dae Ik Yi, Josiah Nathan Joco Perez, Monica Liu, Steven D. Chang, Meredith J. Barad, Michael Lim, and Xiang Qian. 2022. "The Molecular Basis and Pathophysiology of Trigeminal Neuralgia" International Journal of Molecular Sciences 23, no. 7: 3604. https://doi.org/10.3390/ijms23073604

APA Style

Chen, Q., Yi, D. I., Perez, J. N. J., Liu, M., Chang, S. D., Barad, M. J., Lim, M., & Qian, X. (2022). The Molecular Basis and Pathophysiology of Trigeminal Neuralgia. International Journal of Molecular Sciences, 23(7), 3604. https://doi.org/10.3390/ijms23073604

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop